Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708513 | 1.00 | VNN1 (0.41) | VNN1MAPK14ADORA2AADORA1BACE1 | |
| SCHEMBL4709546 | 0.84 | KDM4E (0.48) | VNN1MAPK14KDM4EDRD2DRD1 | |
| SCHEMBL4708654 | 0.83 | VNN1 (0.38) | VNN1KDM4EDRD2DRD1DRD4 | |
| SCHEMBL4707889 | 0.83 | VNN1 (0.38) | VNN1KDM4EDRD2DRD1DRD4 | |
| SCHEMBL5062220 | 0.80 | KDM4E (0.43) | KDM4ELMNAMAPTHPGDHSD17B10 | |
| SCHEMBL5034761 | 0.76 | CYP1A2 (0.45) | VNN1MAPK14LMNAHPGD | |
| SCHEMBL9575546 | 0.73 | NPC1 (0.47) | VNN1MAPK14LMNA | |
| SCHEMBL4707952 | 0.72 | MAPT (0.59) | MAPK14KDM4ELMNACYP3A4MAPT | |
| SCHEMBL4709783 | 0.72 | VNN1 (0.52) | VNN1MAPK14LMNAMAPTHPGD | |
| SCHEMBL4709037 | 0.71 | VNN1 (0.51) | VNN1MAPK14LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556055-B1 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY | VIA PHARMACEUTICALS INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | disclosed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | PDE7A, PDE4A, PDE4B | VNN1 456/4885MAPK14 2935/4885ADORA2A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.